Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Viral clearance 79% Improvement Relative Risk Time to viral- 41% primary Viral clearance (b) 32% late c19early.com/pl Li et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Li, 399 patient paxlovid early treatment study: 79% improved viral clearance [p<0.0001] https://c19p.org/li16
copied to clipboard
Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19
Li et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac600
23 Jul 2022    Source   PDF   Share   Tweet
Retrospective 258 paxlovid patients and 224 patients before paxlovid was available in China, showing significantly faster viral clearance with treatment. Adjusted results are only provided for subgroups (≤5, >5 days from onset). Patients that discontinued treatment due to side effects were excluded. The treatment and control groups were separated in time. Control patients were hospitalized later, median 3 days [2-5] vs. 2 [1-3], suggesting that during the time period for treatment, patients were treated earlier.
risk of no viral clearance, 79.4% lower, HR 0.21, p < 0.001, treatment 18 of 175 (10.3%), control 130 of 224 (58.0%), NNT 2.1, adjusted per study, model 2, multivariable, day 15.
time to viral-, 41.2% lower, relative time 0.59, p < 0.001, treatment 175, control 224, ≤5 days, primary outcome.
risk of no viral clearance, 32.0% lower, HR 0.68, p = 0.04, treatment 40 of 83 (48.2%), control 130 of 224 (58.0%), adjusted per study, >5 days, model 2, multivariable, day 15, late treatment result.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 7/23/2022, retrospective, China, peer-reviewed, 20 authors, study period 5 March, 2022 - 5 April, 2022.
Contact: zhengyang@jlu.edu.cn.
All Studies   All Outcomes
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit